Advertisement
At close: 04:00PM EST
After hours:
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 30.47 |
| Open | 28.97 |
| Bid | 28.87 x 4000 |
| Ask | 28.87 x 4000 |
| Day's Range | 28.30 - 29.40 |
| 52 Week Range | 28.30 - 54.93 |
| Volume | |
| Avg. Volume | 30,620,631 |
| Market Cap | 163.238B |
| Beta (5Y Monthly) | 0.58 |
| PE Ratio (TTM) | 15.80 |
| EPS (TTM) | 1.83 |
| Earnings Date | Jan 29, 2024 - Feb 02, 2024 |
| Forward Dividend & Yield | 1.64 (5.67%) |
| Ex-Dividend Date | Nov 09, 2023 |
| 1y Target Est | 40.10 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
8% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for PFE
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Pfizer, Inc.Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.RatingFair ValueEconomic Moat2 days agoMorningstar
Motley FoolIs Pfizer Stock a Buy Now?
Pfizer (NYSE: PFE), known for its billion-dollar coronavirus products -- the vaccine Comirnaty and the treatment Paxlovid -- saw its shares drop about 40%. This includes Pfizer's newer programs and what they may deliver in the future, as well as the company's valuation today. Is Pfizer a buy right now -- or a stock to avoid?
Motley FoolWhy I'm Considering Selling Pfizer for Tax-Loss Harvesting Purposes
One stock I'm considering letting go is pharma giant Pfizer (NYSE: PFE). Here are two other issues driving me toward hitting the "sell" button on this pharma stock. Since Albert Bourla took over as CEO in 2019, Pfizer has been on a buying spree.
Motley FoolAn Important History Lesson for Gene-Editing Investors
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.